Biotech | October 15, 2021
Exelixis in-licenses second anti-cancer compound from Aurigene
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The transaction is anticipated to close in the first quarter of 2022
The 462,000 square foot state-of-the-art building targeting LEED Zero certification and is designed to be the most sustainable commercial lab building in Cambridge
The acquisition complements and strengthens Merck’s cardiovascular pipeline
Lifebit's accompanying suite of AI-powered end-to-end software solutions provide faster data insights, accelerate drug discovery pipelines, and improve clinical trials success
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
Subscribe To Our Newsletter & Stay Updated
